This announcement is a separate document:
中源协和细胞基因工程股份有限公司关于全资子公司VUM02注射液用于治疗特发性肺纤维化首例受试者完成入组给药的公告
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on the completion of group administration of its wholly-owned subsidiary VUM02 injection to treat the first case of idiopathic pulmonary fibrosis
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.